Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Simcere Zaiming Pharmaceutical Co. Ltd. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being handled by several distinct examiners, which means that each pending matter is currently under the review of a different individual. Furthermore, the prosecution is taking place across 3 distinct art units, indicating that applications are classified within different specialized sections of the patent office.
The busiest examiner for this portfolio is Lee, William Y, who is managing 1 pending office action. Since there are multiple pending office actions in total, the workload is split among the examiners involved. This distribution suggests that the company's current patent strategy is not concentrated in any single examiner's hands, but rather spread across different areas of the biotechnology sector.
For a practitioner, the fact that the involved art units are distinct means that the prosecution of these matters may follow different timelines or examination trends. The company must be prepared to address the specific requirements of each examiner. This decentralized approach ensures that the progress of one application is unlikely to directly impact the others.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.8% | +46.5% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684477 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, WILLIAM Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266125 | ANTI-EGFR NANOBODY AND USE THEREOF | SHUPE, ELIZABETH A | 19d |
| 18684477 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, WILLIAM Y | — |
| 18266393 | GPC3 ANTIBODY AND APPLICATION THEREOF | DONOGHUE, BRITTNEY ERIN | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1675 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684477 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, WILLIAM Y | 1623 | §102§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18266393 | GPC3 ANTIBODY AND APPLICATION THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18266125 | ANTI-EGFR NANOBODY AND USE THEREOF | SHUPE, ELIZABETH A | 1643 | §112 | Final Rejection | 19d | Pending | Jun 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial